Dec 29, 2025 • MarketBeat
NEUTRAL
Osaic Holdings Inc. Raises Stake in Medpace Holdings, Inc. $MEDP
Osaic Holdings Inc. increased its stake in Medpace Holdings, Inc. by 55.4% during Q2, now holding 6,334 shares valued at $1.99 million, contributing to institutional ownership of nearly 78%. Despite significant insider selling totaling over $233 million in the last 90 days, analysts maintain a consensus "Hold" rating with a target price of $490.82, contrasting with the current trading price around $567.56. Medpace recently reported strong Q3 earnings, exceeding analyst estimates for both EPS and revenue.
Dec 28, 2025 • MarketBeat
NEUTRAL
Medpace Holdings, Inc. $MEDP Shares Sold by PineStone Asset Management Inc.
PineStone Asset Management Inc. reduced its stake in Medpace Holdings, Inc. by 19.6% in the third quarter, while institutional investors collectively own 77.98% of the stock. Despite significant insider selling over the past three months, Medpace's fundamentals remain strong, with the company beating Q3 earnings expectations and providing optimistic FY2025 EPS guidance. Wall Street analysts currently give the stock a "Hold" rating with an average target price of $490.82.
Dec 28, 2025 • MarketBeat
SOMEWHAT-BULLISH
Cwm LLC Has $14.65 Million Holdings in Medpace Holdings, Inc. $MEDP
Cwm LLC significantly increased its stake in Medpace Holdings, Inc. ($MEDP) by 311.4% in Q3, now owning 28,496 shares valued at $14.65 million. Despite substantial insider selling that totaled $233.39 million, institutional ownership remains high, and Medpace recently exceeded EPS and revenue estimates, providing optimistic FY2025 guidance. Wall Street analysts currently hold a mixed "Hold" rating with an average target price of $490.82.
Dec 27, 2025 • MarketBeat
SOMEWHAT-BEARISH
Rice Hall James & Associates LLC Decreases Stock Holdings in Medpace Holdings, Inc. $MEDP
Rice Hall James & Associates LLC reduced its stake in Medpace Holdings, Inc. by 10.8% in Q3, selling 11,045 shares and retaining 91,409 shares valued at $46.999 million. This adjustment makes Medpace its 4th-largest holding, representing about 2.6% of its portfolio. Despite this reduction and recent significant insider selling, Medpace exceeded Q3 earnings and revenue estimates, though analyst consensus remains a "Hold" with a price target below current share price.
Dec 27, 2025 • MarketBeat
NEUTRAL
Pacer Advisors Inc. Buys 68,384 Shares of Medpace Holdings, Inc. $MEDP
Pacer Advisors Inc. significantly increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 159.4%, purchasing 68,384 additional shares to own a total of 111,290 shares valued at approximately $57.22 million. Despite this institutional buying, Medpace has seen substantial insider selling, with President Jesse J. Geiger and CEO August J. Troendle collectively offloading over 80,000 shares worth millions. The company recently exceeded Q3 earnings estimates and provided optimistic FY2025 guidance, yet analysts maintain a consensus "Hold" rating with a price target of $490.82.
Dec 23, 2025 • 富途牛牛
NEUTRAL
A Look At The Intrinsic Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
This article estimates the intrinsic value of Medpace Holdings, Inc. (NASDAQ: MEDP) using a 2-stage Discounted Cash Flow (DCF) model and concluding it trades close to its estimated fair value of US$678. The analysis incorporates future cash flow forecasts and discusses key assumptions like the discount rate and growth phases. It also includes a brief SWOT analysis and advises investors to consider additional factors beyond valuation.